Clinical Trial Update: Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

View source ↗

Summary

A completed real-world study by Regeneron evaluating clinical outcomes in patients with relapsed and refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed and Refractory Multiple Myeloma (RRMM) | Status: COMPLETED